Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population

SIMPLE SUMMARY: Monotherapy with pembrolizumab is the standard of first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed Death ligand-1 (PD-L1) tumor proportion score (TPS) ≥ 50%. However, pembrolizumab outcomes in real-world settings seem to be lower tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Galán, Rocío Jiménez, Prado-Mel, Elena, Pérez-Moreno, María Antonia, Caballano-Infantes, Estefanía, Flores Moreno, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472602/
https://www.ncbi.nlm.nih.gov/pubmed/34571767
http://dx.doi.org/10.3390/biology10090890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472602/
https://www.ncbi.nlm.nih.gov/pubmed/34571767
http://dx.doi.org/10.3390/biology10090890

Ejemplares similares